Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.41 |
| ▸ | HTR2C | P28335 | 12/20 | 0.41 |
| ▸ | HTR2B | P41595 | 12/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475010 | 0.86 | PDE4B (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL4475013 | 0.86 | PDE4B (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL4472513 | 0.85 | HTR2A (0.56) | HTR2AHTR2CHTR2B | |
| SCHEMBL4476233 | 0.85 | HTR2A (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL4473318 | 0.84 | HTR2A (0.43) | HTR2AHTR2CHTR2B | |
| SCHEMBL13763140 | 0.82 | HTR2A (0.43) | HTR2AHTR2CHTR2B | |
| SCHEMBL4484134 | 0.81 | HTR2A (0.60) | HTR2AHTR2CHTR2B | |
| SCHEMBL4464501 | 0.81 | HTR2A (0.60) | HTR2AHTR2CHTR2B | |
| SCHEMBL4482456 | 0.81 | HTR2A (0.60) | HTR2AHTR2CHTR2B | |
| SCHEMBL4465991 | 0.80 | GAA (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572805-B2 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | HTR2B, OPRD1, HTR1B | HTR2A 31/4885HTR2C 17/4885HTR2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.